Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Group 1 - Collegium Pharmaceutical reported $181.95 million in revenue for Q4 2024, a year-over-year increase of 21.5% [1] - The EPS for the same period was$ 1.77, compared to $1.58 a year ago, representing a surprise of +14.94% over the consensus estimate of$ 1.54 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $180.4 million by +0.86% [1] Group 2 - Total product revenues for Belbuca were$ 55.21 million, exceeding the average estimate of $53.96 million, with a year-over-year change of +12% [4] - Xtampza ER generated$ 51.45 million in revenue, surpassing the estimated $49.96 million, reflecting a +9.7% change year-over-year [4] - Symproic's revenue was$ 4.25 million, below the average estimate of $3.92 million, showing a year-over-year decline of -16.4% [4] - Nucynta reported$ 41.75 million in revenue, which was lower than the estimated $43.52 million, indicating a -13.8% year-over-year change [4] - Jornay PM achieved$ 29.28 million in revenue, slightly above the average estimate of $28.86 million [4] Group 3 - Collegium Pharmaceutical's shares have returned -12.6% over the past month, compared to the Zacks S&P 500 composite's -2.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]